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CASE PRESENTATION
A 76-year-old white male with hypertension, progressive
renal insufficiency, and proteinuria of unclear etiology was
admitted for renal biopsy in June 2005. His kidney disease
had steadily progressed over the past 3 years. On
admission, he complained of fatigue with increased
daytime somnolence, loss of appetite, weight loss, and
increased itching. There was no nausea, vomiting, or other
uremic symptoms. Review of systems revealed mild cold
intolerance, complaints of occasional mild non-exertional
chest pains lasting minutes, and bilateral knee pain. There
were no neurologic symptoms.
His past medical history was notable for gout, glaucoma,
arthritis, hypertension, and chronic kidney disease. There
was no history of any invasive vascular procedure, use of
radio-contrast agent, or treatment with anticoagulant or
thrombolytic agents. He had been taking amlodipine,
hydrochlorothiazide, enalapril, and atorvastatin before
admission. He was a nonsmoker and not a current alcohol
user. On examination, he was a well-oriented alert elderly
male, his peripheral pulse rate was 57 beats/minute regular
in rate and rhythm, and his blood pressure was 153/
77 mm Hg. His lower extremities were well perfused with no
ischemic or gangrenous lesions. There was no livedo
reticularis and no muscle tenderness. He did not have
peripheral edema. Laboratory investigations (Table 1)
revealed a white blood cell count of 5.86 K/ml, with a normal
differential count and no evidence of eosinophilia. His blood
urea nitrogen was 53 mg/dl, serum creatinine 4.4 mg/dl, and
an estimated glomerular filtration rate was 14 ml/min/
1.73 m2. Urine dipstick showed a urine albumin of 3þ , and
the sediment revealed 2–3 white blood cells and 0–1 red
blood cell/high power field. Spot protein/creatinine ratio
was 4.7 mg/g of creatinine. Chest X-ray revealed
cardiomegaly with a tortuous atherosclerotic aorta.
RENAL BIOPSY
A total of seven glomeruli were present: two were globally
obsolescent and three showed focal segmental glomerulo-
sclerosis. The remaining two glomeruli appeared mildly
hypertrophic with mild mesangial hypercellularity and a
slight expansion of mesangial matrix. Double contours were
noted focally in capillary wall segments. The larger arteries
displayed vascular sclerosis of the media with hyaline intimal
thickening. Elongated, empty, cleft-like crystal spaces lodged
within and occluding the lumina of an arteriole characteristic
of cholesterol crystal emboli were observed (Figure 1).
Cholesterol emboli were also noted in the wall of an
interlobular artery in the tolidine blue-stained sections
submitted for electron microscopic examination. There was
no perivascular inflammation. Areas of ischemic injury with
parenchymal scarring, extensive tubular atrophy, thickening
of tubular basement membranes, numerous periodic acid-
Schiff-positive casts within atrophic tubules and extensive
interstitial fibrosis (90%) were present (Figure 2). Immuno-
fluorescence revealed no significant immune deposits, with
only segmental IgM deposits (þ þ þ /4þ ) and C3 (þ þ /
4þ ) in two glomeruli. On electron microscopy, there was
marked visceral epithelial cell foot process fusion with micro-
villous formation. Isolated loops revealed double contours
and occasional sub-epithelial humps were seen along the
capillary loops. The mesangial matrix showed a marked
increase without electron dense/lucent deposits.
DIAGNOSIS
A diagnosis of progressive kidney failure secondary to
spontaneous atheroembolic (AE) disease and small-vessel
vascular disease was made. This was largely based on the
kidney biopsy findings, which showed moderately severe
vascular sclerosis, with AE disease; advanced focal and
segmental glomerulosclerosis, secondary to vascular disease
and potentially secondary to superimposed functional and
structural adaptations. The presence of an occasional sub-
epithelial ‘hump’-like deposit suggested the possibility of a
prior and currently inactive episode of post-infectious
glomerulonephritis.
CLINICAL FOLLOW UP
The patient’s blood pressure was managed with amlodipine
10 mg/day and enalapril 5 mg/day. He also received 10 mg day
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of atorvastatin for his hypercholesterolemia. Over the next 8
months, his serum creatinine increased from 4.4 to 5.7 mg/dl
(estimation of glomerular filtration rate of 10 ml/min/
1.73 m2) and he continued to have proteinuria. He developed
worse uremia. Hence, he was initiated on hemodialysis in
February 2006. As of January 2007, he has remained stable on
chronic maintenance hemodialysis.
DISCUSSION
This patient presented clinically with progressive renal failure
of unclear etiology. A diagnosis of AE renal disease was made
on the basis of the renal biopsy. The presentation illustrates
the importance of considering a wide differential diagnosis in
elderly patients who present with progressive renal failure.
Furthermore, the absence of precipitating factors or clinical
stigmata of AE should not necessarily deter clinicians from
considering this possibility in the differential diagnosis. The
kidney biopsy showed prominent vascular disease with
characteristic AE and cortical scarring. The advanced
segmental and global sclerosis of glomeruli was probably
secondary to the prominent vascular disease. In point of fact,
the finding of sub-epithelial ‘hump’-like deposits and intra-
membranous deposits in the capillary loops without the
changes by immunofluorescence microscopy suggests a
previous episode of acute post-infectious glomerulonephritis,
which is currently quiescent. The early nodular expansion of
the mesangium noted in this biopsy is also unusual in the
absence of diabetes mellitus. Other processes that could have
led to the development of nodular glomerulosclerosis include
healed mesangiolysis in patients with thrombotic angiopa-
thies and paraprotein deposition disease, both of which were
ruled out in this patient.
Osler is quoted as saying ‘It is much more important to
know what sort of a patient has a disease than what sort of a
disease a patient has.’ This is underscored by the presentation
reported herein. The absence of any history of vascular
intervention or the use of anti-coagulant or thrombolytic
Table 1 | Laboratory findings
Date 6/22/05 1/06 2/06 9/06 11/06 12/06 1/07
Serum/blood
BUN (mg/dl) 53 36/19a 34 43/13a 58/15a
Creatinine (mg/dl) 4.4 4.0 4.9 5.6 6.7
MDRD-GFR ml/min/1.73 m2 14 16 12 10 9
Absolute eosinophil count (peripheral) (K/ml) 0.15 0.01 0.08 0.17 0.13 0.12
Urinalysis
Blood Trace 3+ 3+
Albumin 3+ 3+ 3+
Urinary eosinophils Nil Nil
Spot creatinine 38.7
Spot protein 184.1
BUN, blood urea nitrogen; MDRD-GFR, Modification of Diet in Renal Disease-glomerular filtration rate.
aPre and post-dialysis values.
Figure 1 | An arteriole displays luminal occlusion by characteristic
biconvex needle-shaped cleft-like empty spaces of cholesterol
emboli. (Trichrome, original magnification  400).
Figure 2 | An area of the submitted tissue shows parenchymal
scarring with a single sclerosed glomerulus, most probably
reflective of the ischemic injury. (PAS, original magnification
 200).
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drugs, and the lack of external evidence of peripheral skin
lesions made the clinical diagnosis of AE challenging. The
only suggestive history was that of an elderly male with
long-standing hypertension and hypercholesterolemia. The
diagnostic lesion of AE was observed on renal biopsy
examination. Indeed, in the absence of livedo reticularis,
cyanosis, or distal gangrene, the diagnosis of AE may escape
detection both in acute as well as chronic presentations
unless a systematic approach of screening for risk factors in
high-risk individuals is instituted. This case presentation
illustrates the importance of considering the diagnosis of AE
in any elderly patient with progressive kidney disease of
unknown cause. The presentation also underscores the
importance of performing a kidney biopsy to definitively
make the diagnosis.
AE, also known as cholesterol embolism, is a well-
described entity, which results from peripheral embolization
of small cholesterol crystals that fracture off of ruptured
atherosclerotic plaques from proximal regions of the
vasculature. Although atheroembolism syndrome was recog-
nized as a clinicopathologic entity more than 50 years ago,1 it
is attracting growing attention because of the exponential
increase in the use of new invasive cardiovascular diagnostic
and therapeutic procedures. With increasing age of renal
transplant donors, it is also increasingly recognized as a cause
of rapid graft failure (related to renal artery atherosclerosis).2
IS ATHEROEMBOLISM A RARE DISEASE OR
UNDER-RECOGNIZED?
There is uncertainty regarding the prevalence and the clinical
significance of AE. The prevalence of AE reported in clinical
series is variable and appears to be dependent on sampling
bias: AE is higher in autopsy series and in studies of selected
populations. One of the earliest reports of AE was by Flory,1
who observed an incidence of 4.4% in consecutive autopsies.
On the other hand, Kealy3 reported a low incidence of 0.79%
in the 2126 autopsies performed in patients over 60 years of
age. However, in the Kealy study, the prevalence of AE among
patients who had underlying risk factors was not reported.3
Thurlbeck and Castleman4 reported an incidence of 77%
among patients who died after abdominal surgery. Mayo and
Swartz5 in their retrospective analysis of all inpatient
nephrology consultations over 7 months observed 4% of
in-patient nephrology consultations, representing approxi-
mately 5–10% of the acute renal failures, attributable to
clinically significant AE. Mayo and Swartz suggest that the
prevalence of AE is high. In their series AE was diagnosed
every 2 weeks.
CLINICAL FEATURES
AE is a multisystem disease and clinical features can be
varied. Multifocal lesions and progressive tissue loss second-
ary to ischemic injury involving the kidney, skin, brain,
myocardium, and intestines that mimic systemic vasculitis or
sub-acute bacterial endocarditis.6–8 Commonly observed
clinical findings include fever, myalgia and hypertension,
livedo reticularis and cyanotic changes in the skin,7,8 and
distal gangrene or necrotic ulcers9,10 are also common.
Extra-renal involvement of central nervous system and
gastrointestinal changes and retinal emboli have been
documented.8 Renal manifestations may vary from acute,
sub-acute, or chronic kidney failure. In addition, kidney
function may transiently improve in AE because areas of
ischemic acute tubular necrosis that may be coincidentally
present spontaneously recover. Peripheral or urinary eosino-
philia and hypocomplementemia are commonly reported
laboratory abnormalities; however, these are most often
transient and mild. Other laboratory abnormalities, such as
raised erythrocyte sediment rate, increased amylase, abnor-
mal liver function tests, and raised creatine phosphokinase, as
well as a positive antinuclear cytoplasmic antibody have all
been reported.11
RISK FACTORS AND ‘TRIGGER’ EVENTS
There is consensus that atherosclerosis is a pre-requisite for
the development of AE. Not surprisingly, the disease is most
commonly observed in those older than 50 years.1 Males are
more commonly affected.10–13 Preferential occurrence in
Caucasians has been observed.11,14 Other risk factors of
vascular obstruction, such as smoking, hypertension, and
diabetes mellitus, have also been reported.9 Spontaneous
detachment of cholesterol emboli in patients with marked
atherosclerotic arterial lesions has been observed15 AE is of
iatrogenic etiology in three quarters of all patients. The
‘trigger’ events for AE are endovascular procedures, vascular
surgery including coronary bypass grafting, and long-term
anticoagulant or thrombolytic therapy.9–11,16–19 AE affecting
the kidney is also a common complication of atherosclerotic
renal artery disease. With higher numbers of donors and
recipients of older age being accepted for transplantation, AE
in renal transplant recipients is probably to become more
common and will be increasingly considered as a cause of
graft dysfunction.2,20 A typical triad of a ‘trigger’ event, sub-
acute renal failure and peripheral lesions in skin/retina
should strongly suggest the diagnosis. ‘Spontaneous’ chole-
sterol embolism, as noted in this case is rare. Cross,15 in a
series of 372 necropsies, estimated the incidence of
spontaneous cholesterol embolism to be 1.9%. Scolari
et al,11 found that in his series of ninety five patients with
AE, 13% had spontaneous AE. The clinical presentation is
usually one of a low-grade clinically silent migration of
crystals from the atherosclerotic plaque. On the other hand,
since the ‘shower’ of cholesterol crystals occurs over a longer
period of time and quite insidiously, it is possible that
patients who present with spontaneous AE have more severe
and complicated atherosclerosis.
PATHOLOGIC FEATURES OF AE
While histological confirmation can be accomplished by
biopsying any of the affected target organs, such as skin or
muscle, the highest diagnostic yield comes from performing a
kidney biopsy.8 However, an important caveat is that since
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cholesterol crystal embolization is a patchy process, a focal
lesion usually ensues. Hence, obtaining an adequate sample
and careful scrutiny of multiple step sections is very
important.
AE is histologically characterized by elongated, biconvex
transparent needle-shaped clefts, which represent the choles-
terol crystals that are dissolved during tissue processing.
These crystals are usually small and may not completely
occlude the vessel lumen; however, they frequently induce an
endothelial inflammatory response, which leads to a
complete obstruction of the vessel within weeks or months.
Ischemia secondary to vascular occlusion leads to glomerular
shrinkage, wrinkling, and apparent thickening of glomerular
basement membrane. Greenberg et al.13 have described
accompanying focal and segmental glomerulosclerosis in
63% of biopsies with AE. In their study, the percentage of
segmentally sclerosed glomeruli, and in particular the cellular
variant of focal and segmental glomerulosclerosis, was higher
in patients with AE and nephrotic range proteinuria.13 A
proportional increase in the interstitial fibrosis and infiltra-
tion with mononuclear cells follows glomerular sclerosis.
Occasionally, other associated conditions with AE have been
noted, and Greenberg13 described one subject with membra-
nous nephropathy along with AE.
AE can be diagnosed on light microscopy. Direct
immunofluorescence microscopy or transmission electron
microscopy is not necessary for the initial diagnosis or
confirmation of the diagnosis. However, both immunofluor-
escence and electron microscopy help in the identification of
other associated lesions in the same biopsy. This point is
underscored by the patient presented here who had a biopsy
showing AE and evidence of a prior immune complex
mediated process that was ultimately recognized on electron
microscopy.
DIFFERENTIAL DIAGNOSIS OF AE
Several conditions can mimic renal involvement in AE. The
common conditions that need to be differentiated clinically
from the chronic presentation of AE are hypertensive
nephrosclerosis and renal artery stenosis. In both, renal
impairment due to either of these conditions may precede the
development of AE; both may be independent determinants
of patient and renal outcome.11 In the presence of acute renal
failure following radiocontrast use, differentiation of AE from
radiocontrast-induced nephrotoxicity is important. Multi-
system involvement noted in polyarteritis, disseminated
angitis, or sub-acute bacterial endocarditis associated with
disseminated thromboembolization may mimic AE. AE can
induce eosinophilia as well as an anti-neutrophil cytoplasmic
antibody negative angitis;6 indeed, reports of perinuclear
anti-neutrophil cytoplasmic antibody have been reported in
the literature, and in such cases, making a differentiation
from true vasculitis becomes even more challenging.21
Immunoallergic interstitial nephritis also presents with acute
renal failure with skin lesions and eosinophilia.22 The range
of differential diagnosis should also include active interstitial
nephritis, acute tubular necrosis, and rapidly progressive
glomerulonephritis. The extensive differential diagnosis
underlines the necessity of histologic confirmation of AE.
The prognosis of AE is generally quite poor.8,23 The cause
of death is usually multiorgan failure due to visceral
ischemia, in particular cardiovascular disease rather than
end-stage kidney failure alone.11,23 The prognosis depends on
the severity and number of comorbid risk factors (Table 2)5
and the number and size of cholesterol crystals. Scolari et al.
have also reported that the age of the patient and the presence
of diabetes mellitus are independent risk factors for patient
mortality in AE renal disease. Male gender was associated
with a decreased risk of mortality. Pre-existing renal
impairment, which probably reflects co-existing often severe
atherosclerosis/arteriolosclerosis has also been demonstrated
to be an independent determinant of patient and renal
outcomes.11,12,24 If AE is detected early, Theriault et al.25 have
reported renal recovery in 12 out of 43 cases with renal failure
requiring dialysis after a mean delay of 4097306 days.
Peripheral eosinophilia was significantly higher in patients
who had recovery of renal function.12
MANAGEMENT OF ATHEROEMBOLISM
There is no definitive treatment for AE; symptomatic and
preventive measures have been advocated. Various treatment
strategies have been pursued including with low-density
lipoprotein apheresis26 and low-dose corticosteroids.27 Sup-
portive measures include angiotensin blockade for pre-
dialysis patients and hemodialysis support for those who
reach end-stage renal disease. Kryvoshey et al.28 have also
reported successful renal transplantation in one patient
following long-term control of atherosclerotic risk factors.
Other important preventive measures include, secondary
prevention of atherosclerotic risk factors, avoiding anti-
coagulant therapy, invasive radiology, and vascular surgery in
subjects with extensive arteriosclerosis. The possibility of
using a brachial approach for aortogram or coronary
angiogram to prevent AE needs to be considered. Statins
have been shown to have a plaque-stabilizing effect, perhaps
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as a result of their cholesterol-lowering effect as well as
anti-inflammatory and immunomodulatory properties.29
Improvement in patient and renal survival with aggressive
management has been documented in some reports.25,30
CONCLUSION
AE is an under-recognized cause of kidney failure. It should
be considered in the differential diagnosis of any patient who
presents with progressive kidney failure, particularly if the
patient is elderly with risk factors for atherosclerosis.
Although poor outcomes have been associated with AE,
early recognition and institution of aggressive therapies
targeted at secondary prevention have been shown to stabilize
and, in a limited number of cases, even improve renal
function. A typical triad of a ‘trigger’ event, sub-acute kidney
failure and peripheral lesions in skin/retina should strongly
suggest the diagnosis. As a number of clinical conditions can
mimic AE clinically, a biopsy diagnosis (skin, muscle, or
kidney) will provide a definitive diagnosis and should be
considered. However, as discussed in the patient presented
here, AE may present with disease limited only to the
kidneys, and a kidney biopsy becomes essential in making a
diagnosis. Avoidance of interventional radiologic procedures,
vascular surgery, and excess anticoagulation in elderly
atherosclerotic patients is sensible but is often unavoidable.
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